T2 Biosystems, Inc.

Report azionario OTCPK:TTOO

Capitalizzazione di mercato: US$19.6k

T2 Biosystems Crescita futura

Criteri Future verificati 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di T2 Biosystems.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili24.7%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamenton/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Apr 18

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

T2 Biosystems, Inc.'s ( NASDAQ:TTOO ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a strong buy...
Seeking Alpha • Oct 13

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems (NASDAQ:TTOO) said on Thursday it had planned to to complete development of, and commercialize, a diagnostic test to detect early Lyme disease. The company expects to begin marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023. "We believe the T2Lyme Panel will potentially allow clinicians to ensure patients receive appropriate therapy faster, and prevent the negative impact of a delay in delivery of appropriate therapy and the overuse of antibiotics,” said John Sperzel, CEO of T2Biosystems. The molecular diagnostic test, T2Lyme panel, is designed to run on the FDA-cleared T2Dx Instrument and to detect Borrelia burgdorferi, the bacteria that causes Lyme disease. Lyme disease is a bacterial infection caused by the genes Borrelia and is transmitted to humans through the bite of infected ticks. About 476,000 Americans may get Lyme disease each year in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).
Seeking Alpha • Sep 29

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

Biomedical Advanced Research and Development Authority (or BARDA) is providing T2 Biosystems (NASDAQ:TTOO) an additional $3.7M in funding for the multiple-year cost-share contract. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The total potential BARDA funding if all contract options are exercised is $62M, reflecting a reduction in the scope of work under contract option 3. "We are pleased to advance the U.S. clinical trials for the T2Resistance Panel and T2Biothreat Panel, in collaboration with BARDA, and subsequently file submissions with FDA for U.S. regulatory clearance. These new products will expand the test menu on our T2Dx Instrument and have the potential to reduce the threat of antimicrobial resistance and protect the nation from biothreat pathogens.” stated John Sperzel, Chairman and CEO.
Seeking Alpha • Sep 22

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems (NASDAQ:TTOO) on Thursday said it had entered into a distribution agreement in the Baltic region for the sale of its products. Shares of the micro-cap diagnostics company jumped 17.3% to $0.10 after hours. It is worth noting that TTOO stock had earlier closed 11.8% lower to notch its eight straight session in the red. As per the agreement with the distributor, TTOO can sell products such as its T2Bacteria Panel, which can identify sepsis-causing bacteria, and its T2Candida Panel, which can detect fungal pathogens. "We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Lithuania, Latvia, and Estonia,” TTOO CEO John Sperzel said in a statement.
Seeking Alpha • Aug 26

T2 Biosystems' Survival Riddle

Summary T2's ongoing survival is a marvel to behold. T2's products fill key niches but have yet to show any viable commercial appeal. The elephant in the room for T2 shareholders is whether it will ever participate in any upside that may reside in its intellectual property. T2 Biosystems (TTOO) is a bygone favorite of mine that has bumped along on the fringes. I last discussed it in 08/2020's "COVID-19 Opportunity Knocks, T2 Answers". At the time, T2 was hoping to use interest in its rapid COVID diagnostics to place its T2Dx diagnostic device in hospitals. T2's strategy has been successful, but at an insufficient scale to turn it around. Placing devices is an important focus of T2's business development strategy. During T2's Q2 2022 earnings call (the "Call"), CEO Sperzel advised that its strategy was playing out as planned. It was gradually transitioning instruments that had been used for processing T2SARS-CoV-2 panels to use for sepsis testing. As a result, T2 has been experiencing an expected decline in COVID testing. [It] view[s] this development as a positive because it allows [it] to convert COVID-driven instruments to sepsis testing. As a reminder, [it] sold 47 T2Dx instruments to hospital microbiology labs during 2020, initially for COVID-19 testing, with the expectation that approximately 80% would convert to ... sepsis test panels over time. Selling instruments is an important driver of revenues for T2. Once an instrument is placed, it generates ongoing revenues. During the Call Sperzel explained: From an instrument pull-through perspective, in the United States, we achieved annualized sepsis tests utilization of $106,000 for legacy instruments. We continue to believe that annualized US sepsis test utilization will reach $200,000 per instrument and we have a number of customers that have already surpassed that target. We believe there is a significant market opportunity for our products, and we're excited to expand our presence in new and existing customers. During the Call, he also advised that T2's installed base of instruments includes a total of 155, 94 in the US and 61 internationally. When you consider that the instrument was FDA approved in 09/2014, this is a discouraging total. T2 has gone from troubled to extremely troubled, but somehow it keeps on ticking. My first (11/2019) T2 article, "T2: Navigating The Danger Zone", presented a cautiously optimistic view of this company. T2 had snagged its FDA approval back in 2014 for its instrument, but was, and still is, wallowing in the danger zone as it works to commercialize its T2Dx diagnostic device. It's hard to believe that T2, which currently (08/25/2022) trades for ~$0.13 went public in 08/2014 at ~$11.00 and subsequently traded >$20.00. Cheap does not a bargain make. T2's current down and nearly out share price reflects some very real problems that are dogging this company. Its rapid diagnostic products are quite attractive from any patient's point of view. The problem is that T2 has yet to figure out how to market them in commercially sufficient quantities to meet its expenses, much less earn a profit. T2's long-fought efforts for commercial viability have decimated the company's shares. It is struggling to maintain its NASDAQ listing. It currently anticipates a reverse stock split of somewhere between 1-for-10 and 1-for-50. If it would elect the 1 for 50 ratio, a shareholder who currently owns 50 shares trading at $0.13 would instead own 1 share worth $6.50; if it elects the 1 for 10 ratio, then shareholder would own 5 shares worth $1.30, still aggregating $6.50. T2 has an outstanding debt financing, originally for $40 million, with CRG. This financing has long been a concern of mine as I discuss at length in "T2: A Catch With A Catch". This concern is only exacerbated by T2's ongoing losses. The CRG loan is secured by a lien on substantially all of T2's assets, including its intellectual property. The loan requires T2 to maintain a minimum cash balance of $5 million along with other covenants. It is prepayable. In its latest 10-K, T2 advises: ...[It] intend[s] to continue to evaluate options to refinance the Term Loan Agreement, which becomes due on December 30, 2023. There can be no assurances that we will be able to refinance on terms favorable or at all. The amounts involved in any such transactions, individually or in the aggregate, may be material. Because the loan and its covenants are so important, T2 advised during the Call that it was then in compliance with all its loan covenants. As I recall from past review, this is a common bit of assurance that T2 has so far been able to provide during its quarterly earnings calls. T2 has a bevy of highly attractive products which have not proven financially viable. The issue with T2 that is especially frustrating relates to the extreme appeal of its products from a patient's point of view. Its current products are shown on its Q2 2022 presentation slide below: seekingalpha.com T2's rapid results are a godsend for patients who need to get a health screening, but who can ill afford long delays that are prevalent in the industry.

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché T2 Biosystems non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:TTOO - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
9/30/20248-43-37-37N/A
6/30/20247-48-44-44N/A
3/31/20247-46-47-47N/A
12/31/20237-50-48-48N/A
9/30/202311-50-49-49N/A
6/30/202313-52-52-52N/A
3/31/202317-64-50-49N/A
12/31/202222-62-51-51N/A
9/30/202224-64-51-50N/A
6/30/202228-61-44-44N/A
3/31/202228-55-45-45N/A
12/31/202128-49-39-39N/A
9/30/202129-47-38-38N/A
6/30/202127-44-35-34N/A
3/31/202123-43-38-37N/A
12/31/202018-47-44-43N/A
9/30/202013-51-45-45N/A
6/30/202010-54-52-52N/A
3/31/20209-59-48-47N/A
12/31/20198-59-46-45N/A
9/30/20197-60-45-45N/A
6/30/20198-57-42-41N/A
3/31/201910-53-42-41N/A
12/31/201811-51-41-40N/A
9/30/201810-54-42-42N/A
6/30/20189-58N/A-43N/A
3/31/20186-61N/A-47N/A
12/31/20175-62N/A-48N/A
9/30/20174-59N/A-47N/A
6/30/20174-57N/A-47N/A
3/31/20174-56N/A-47N/A
12/31/20164-55N/A-46N/A
9/30/20164-52N/A-45N/A
6/30/20164-51N/A-45N/A
3/31/20164-48N/A-42N/A
12/31/20153-45N/A-37N/A
9/30/20152-42N/A-37N/A
6/30/20151-40N/A-33N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista TTOO è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di TTOO cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di TTOO cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di TTOO cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di TTOO cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di TTOO è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/07 10:47
Prezzo dell'azione a fine giornata2026/05/07 00:00
Utili2024/09/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

T2 Biosystems, Inc. è coperta da 10 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Benjamin HaynorAlliance Global Partners
Paul KnightBrean Capital Historical (Janney Montgomery)
Karen KoskiBTIG